Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

This is an observational study (no experimental treatment) for men in Russia with a newly diagnosed advanced form of prostate cancer that has spread to other parts of the body, but still responds to hormone therapy. Researchers want to understand how this cancer is treated in real-world practice and to analyze specific genetic markers in the tumor's DNA found in the blood. **You may be eligible if...** - You are male, aged 18 or older - You have been newly diagnosed with metastatic hormone-sensitive prostate cancer (cancer that has spread but still responds to hormone-lowering treatment) - Your cancer is high-grade (Gleason score 8–10) and has spread extensively (e.g., 4+ bone metastases, or spread to organs) - You have had genetic testing done on your tumor tissue as part of routine care - Your medical records are accessible for review **You may NOT be eligible if...** - You have already enrolled in any other interventional clinical trial since your metastatic diagnosis - Your cancer has already stopped responding to hormone therapy (progressed to castration-resistant prostate cancer) Talk to your doctor to see if this trial is right for you.